Alliance Boots Doubles Down In China With 12% Stake Of Nanjing Pharma
This article was originally published in PharmAsia News
As MNCs increase stakes in China’s pharmaceutical distribution market, the highly segmented nature of the industry will remain a challenge for market penetration, analysts say.
You may also be interested in...
Major UK pharmaceutical and beauty products distributor Alliance Boots announced the appointment of retired Zuellig Pharma CEO Fritz Horlacher to head its heathcare division in Asia. The company aims to expand in Asia, especially in Thailand and Korea, which will pose a big challenge to Zuellig and other heavyweight pharmaceutical distributors
Cardinal Health's recent acquisition of Zuellig Pharma China (Yong Yu in Chinese) likely will not be the last China-based distributor the U.S. wholesaler will pick up, according to company CFO Jeff Henderson
Regardless of who wins, China seems to be looking beyond the 3 November US General Election, instead pouring in large resources to elevate its domestic health sector on a par with international standards, creating opportunities and profoundly impacting many areas from novel therapy development to investment decisions.